Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
29.08
+0.18 (0.62%)
Oct 29, 2026, 10:25 AM EDT - Market open
Zymeworks Revenue
Zymeworks had revenue of $3.23M in the quarter ending June 30, 2026, a decrease of -90.98%. This brings the company's total for the last twelve months to $35.77M, down -67.47% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth. That makes Zymeworks the 29,971st largest company in the world by revenue and 3,976th in the United States.
Revenue (ttm)
$35.77M
Revenue Growth
-67.47%
P/S Ratio
55.24
Revenue / Employee
$160,723
Employees
231
Market Cap
2.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.13B |
| Vericel | 306.30M |
| Vir Biotechnology | 303.23M |
| Septerna | 98.88M |
| Generate Biomedicines | 26.48M |
| ADARx Pharmaceuticals | 6.13M |
| Immunome | 4.02M |
ZYME News
- 2 days ago - Zymeworks Transcript: Investor update - Transcripts
- 2 days ago - Zymeworks Press release: Investor update - Filings
- 2 days ago - Zymeworks Slides: Investor update - Filings
- 2 days ago - Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors - Business Wire
- 3 days ago - Zymeworks Proxy statement: Proxy filing - Filings
- 3 days ago - Zymeworks Proxy statement: Proxy filing - Filings
- 3 days ago - Zymeworks presents new clinical data from Phase 1 study of ZW191 - TheFly
- 3 days ago - Zymeworks presents new clinical data on Phase 1 study of ZW191 - TheFly